Spineway SA ALSPW

H1 2026 results Continued growth Stable resultsStrong embedded growth driversIssuance of straight bonds to finance future growth In thousands of eurosConsolidated financial statements – UnauditedH1 2026H1 2025Revenue5,7255,573Cost of sales(1,882)(1,702)Gross margin% of revenue3,84367%3,87069%Net operating expenses Of which general operating costs(5,489) (2,107)(5,068) (2,086)Of which personnel expensesOf which other op. income and expensesOf which dep., amort., and provisions(2,467)(512)(403)(2,

Ecully, April 30, 2026 – 6:00 p.m. First-quarter 2026 revenue High order volumeSlower-than-expected normalization of supply chains2026: growth trajectory confirmed In thousands of euros20262025Change as a %Q1 revenue2,1762,828-23% Unaudited consolidated data Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.2 million in the first quarter of 2026. Following strong growth in the fourth quarter of 2025 (+38%), the slowdown observed in

Ecully, April 7, 2026 – 8:00 a.m. SPINEWAY Minutes of the General Meeting of April 2, 2026 The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Thursday 2 April 2026 at 10.00 am at the company’s registered office, 7 allée Moulin Berger in Ecully (69). The defaulting shareholders were represented by SELARL TULIER POLGE ALIREZAI, as ad hoc representative appointed by Order of the President of the Lyon Commercial Court dated February 24, 202

Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands of euros Revenue12,43011,950 11,950Cost of sales-3,783-3,699 -3,699Gross margin 8,6478,250 8,250% of revenue69,6%69,0% 69%Net operating expenses-10,780-10,227 -9,131Of which external expenses-3,967-3,522 -3,646Of which personnel expenses-4,600-4,890 -4,890 Of which other op. income and expenses-